[go: up one dir, main page]

SE8903529D0 - Medical use - Google Patents

Medical use

Info

Publication number
SE8903529D0
SE8903529D0 SE8903529A SE8903529A SE8903529D0 SE 8903529 D0 SE8903529 D0 SE 8903529D0 SE 8903529 A SE8903529 A SE 8903529A SE 8903529 A SE8903529 A SE 8903529A SE 8903529 D0 SE8903529 D0 SE 8903529D0
Authority
SE
Sweden
Prior art keywords
pct
bone
date
sec
disease
Prior art date
Application number
SE8903529A
Other languages
English (en)
Inventor
M Hersloef
Original Assignee
M Hersloef
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M Hersloef filed Critical M Hersloef
Priority to SE8903529A priority Critical patent/SE8903529D0/sv
Publication of SE8903529D0 publication Critical patent/SE8903529D0/sv
Priority to NZ235610A priority patent/NZ235610A/xx
Priority to IL9597990A priority patent/IL95979A/en
Priority to JP2514919A priority patent/JPH05501409A/ja
Priority to HU921364A priority patent/HUT60919A/hu
Priority to PCT/SE1990/000684 priority patent/WO1991006296A1/en
Priority to US07/849,020 priority patent/US5354773A/en
Priority to EP90916159A priority patent/EP0497845A1/en
Priority to CA002071914A priority patent/CA2071914A1/en
Priority to AU66229/90A priority patent/AU641445C/en
Priority to IE379390A priority patent/IE903793A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE8903529A 1989-10-24 1989-10-24 Medical use SE8903529D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE8903529A SE8903529D0 (sv) 1989-10-24 1989-10-24 Medical use
NZ235610A NZ235610A (en) 1989-10-24 1990-10-09 Treating bone diseases with bafilomycin-type compounds
IL9597990A IL95979A (en) 1989-10-24 1990-10-12 Pharmaceutical preparations containing phylomycins
AU66229/90A AU641445C (en) 1989-10-24 1990-10-22 Bafilomycine macrolides for treatment of bone affecting diseases
HU921364A HUT60919A (en) 1989-10-24 1990-10-22 Process for producing pharmaceutical compositions comprising bafilomycin macrolids
JP2514919A JPH05501409A (ja) 1989-10-24 1990-10-22 医学的使用
PCT/SE1990/000684 WO1991006296A1 (en) 1989-10-24 1990-10-22 Bafilomycine macrolides for treatment of bone affecting diseases
US07/849,020 US5354773A (en) 1989-10-24 1990-10-22 Use of bafilomycine and derivatives to treat bone diseases
EP90916159A EP0497845A1 (en) 1989-10-24 1990-10-22 Bafilomycine macrolides for treatment of bone affecting diseases
CA002071914A CA2071914A1 (en) 1989-10-24 1990-10-22 Bafilomycine macrolides for treatment of bone affecting diseases
IE379390A IE903793A1 (en) 1989-10-24 1990-10-23 Medical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8903529A SE8903529D0 (sv) 1989-10-24 1989-10-24 Medical use

Publications (1)

Publication Number Publication Date
SE8903529D0 true SE8903529D0 (sv) 1989-10-24

Family

ID=20377263

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8903529A SE8903529D0 (sv) 1989-10-24 1989-10-24 Medical use

Country Status (10)

Country Link
US (1) US5354773A (sv)
EP (1) EP0497845A1 (sv)
JP (1) JPH05501409A (sv)
CA (1) CA2071914A1 (sv)
HU (1) HUT60919A (sv)
IE (1) IE903793A1 (sv)
IL (1) IL95979A (sv)
NZ (1) NZ235610A (sv)
SE (1) SE8903529D0 (sv)
WO (1) WO1991006296A1 (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324720A (en) * 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
US5306716A (en) * 1992-03-20 1994-04-26 Merck & Co., Inc. Methods of achieving antileukemia activity using 16-membered-macrolide-type compounds
EP0639644A1 (de) * 1993-08-16 1995-02-22 Ciba-Geigy Ag Neue Makrolide und ihre Verwendung
DE19828068C2 (de) * 1998-06-24 2003-12-18 Peter Dietsch Mittel zur spezifischen Hemmung osteoklastärer Knochenresorption
US6416737B1 (en) 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
ES2165747A1 (es) * 1999-01-20 2002-03-16 Smithkline Beecham Sa Depsipeptidos como inhibidores de resorcion de hueso.
DE10040052A1 (de) * 2000-08-11 2002-03-07 Univ Eberhard Karls Verwendung von Protonenpumpen-Hemmern zur Behandlung von Entzündungen, insbesondere von Erkrankungen des Bewegungsapparates
AU2002349211A1 (en) * 2001-11-29 2003-06-10 John E Davies Resorption-controlled bone implants
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
CN104817547B (zh) * 2015-03-17 2016-02-24 农业部环境保护科研监测所 新型巴弗洛霉素、其提取微生物和提取方法
EP4263516A1 (en) * 2020-12-16 2023-10-25 The Regents of The University of Michigan Inhibitors of nef downmodulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310533A1 (de) * 1983-03-23 1984-09-27 Bayer Ag, 5090 Leverkusen Organisch-chemische verbindungen und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
JPH05501409A (ja) 1993-03-18
WO1991006296A1 (en) 1991-05-16
HU9201364D0 (en) 1992-07-28
CA2071914A1 (en) 1991-04-25
AU6622990A (en) 1991-05-31
NZ235610A (en) 1993-09-27
US5354773A (en) 1994-10-11
HUT60919A (en) 1992-11-30
IL95979A (en) 1995-11-27
IE903793A1 (en) 1991-04-24
AU641445B2 (en) 1993-09-23
EP0497845A1 (en) 1992-08-12

Similar Documents

Publication Publication Date Title
SE8704248D0 (sv) Medical use
GB9408577D0 (en) New compound
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EP0881908A4 (en) USE OF FIBROBLAST GROWTH FACTORS FOR STIMULATING BONE GROWTH
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
IL113941A (en) Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them
HUT77627A (hu) 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények
RU94044454A (ru) Ингибитор аутоимунных заболеваний
SE8903529D0 (sv) Medical use
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
EP0269311A3 (en) Methods of treating bone diseases by administration of a cysteine proteinase inhibitor
MY103790A (en) Novel compound for the treatment of several bone affecting diseases
SE9003887L (sv) Cellproliferationsmatris och anvaendning daerav
NO965228L (no) Pyridylbisfosfonater for anvendelse som terapeutisk middel
PT99864A (pt) Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
SE8704436D0 (sv) Anvendning av antisekretoriska substanser for nya indikationer
EP0743065A3 (en) Vanadium compounds for inhibiting bone loss
ATE214926T1 (de) Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit
HU9503099D0 (en) New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components
HU9302188D0 (en) Method for producing acylamino-alkylidene-hydroxi-biphosphonic acid derivatives as well as one for producing medical preparatives containing said compounds
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
MX9606180A (es) Piridilbisfosfonatos para utilizarse como un agente terapeutico.